<DOC>
	<DOCNO>NCT00181220</DOCNO>
	<brief_summary>The propose study test safety efficacy sodium valproate induction Epstein-Barr virus ( EBV ) lytic cycle antigen expression tumor tissue patient undergoing primary therapy nasopharyngeal carcinoma . Up 20 patient give valproic acid 2 week . The primary surrogate endpoint efficacy expression EBV lytic antigen immunohistochemistry tumor tissue . Biopsies primary tumor take 2 week achievement therapeutic concentration valproate . Expression immunodominant EBV latency antigens tumor tissue , EBV viral load real time PCR , valproate level measure . Adverse event associate valproate NPC patient describe .</brief_summary>
	<brief_title>Valproic Acid Induction EBV Lytic Cycle Antigen Expression Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>All subject must fulfill follow criterion eligible study admission : Subjects age 18 year Biopsy proven nasopharyngeal carcinoma – WHO type 3 Must tumor accessible biopsy For patient disease localized PNS , lesion must visualize endoscopy Subjects metastatic disease disease accessible biopsy PNS deem treating physician require treatment least two week . An ECOG performance status 0–2 For sexually active woman childbearing potential , negative pregnancy test within 14 day enrol trial Must able give inform consent For patient localized NPC , PNS lesion visualize endoscopy Patients disease inaccessible biopsy History anaphylaxis exposure valproic acid Hepatic dysfunction define total bilirubin 1.0x upper limit normal . AST ( SGOT ) ALT ( SGPT )  3x upper limit normal Hemoglobin  8g/dl , Absolute neutrophil count 1500 cells/mm , Platelet count 100,000 /mm Creatinine 3x upper limit normal PT/PTT blood test result within normal range Patients require treatment anticonvulsant besides valproic acid course valproate prescribe protocol ECOG Performance status 34 Patients pregnant breast feeding ( Sexually active woman childbearing potential must use contraception course therapy within 4 week completion trial ) Participation another clinical trial involve therapeutic intervention within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>